Litcius/Paper detail

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

Shuo Song, Bing Zhou, Lin Cheng, Weilong Liu, Qing Fan, Xiangyang Ge, Hua Peng, Yang‐Xin Fu, Bin Ju, Zheng Zhang

2022Virology Journal22 citationsDOIOpen Access PDF

Abstract

The current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies.

Topics & Concepts

ImmunogenicityVirologyHeterologousImmunizationNeutralizing antibodyVaccinationNeutralizationBiologyAntibodyBooster dosePandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)ImmunologyMedicineInfectious disease (medical specialty)VirusDiseaseGeneticsGenePathologySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies
Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice | Litcius